Retinal Fluid Volatility Associated With Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial.

Purpose: To describe longitudinal retinal fluid dynamics on spectral domain OCT and to identify imaging biomarkers that predict the worsening of DME with interval extension during anti-vascular endothelial growth factor (VEGF) therapy.

Design: A post hoc sub-analysis of phase III, VISTA-DME study.

Methods: Eyes received either intravitreal aflibercept injection 2 mg every 4 weeks (2q4) or every 8 weeks after 5 initial monthly injections (2q8), and eyes imaged with the Cirrus HD-OCT system were included.

Treating postpartum depression with brexanolone.

The FDA has approved brexanolone specifically for treatment of adults with postpartum depression (PPD). Administered I.V.